Expression of p16 and p53 proteins in cervical cancer cases in a tertiary centre in Ghana: an immunohistochemical study Authors: Babatunde Moses Duduyemi, Betty Nkansah Osei Mensah, Ebenezer Kojo Addae, Lorraine Sallah, Kweku Bedu-Addo Published: 2026 ABSTRACT AbstractBackgroundCervical cancer remains a major public health concern in Ghana, with limited screening coverage and late-stage presentation. Biomarkers such as p16 and p53 have been explored for their diagnostic and prognostic relevance in cervical cancer. The study aims to elucidate the possibility of using p16 immunohistochemistry as a surrogate marker for HPV infection in cervical cancer among other things and role of p53 in cervical cancer.MethodsA retrospective descriptive study was conducted on 135 Formalin-Fixed-Paraffin-Embedded archived cervical tissue samples at a tertiary facility in Kumasi, Ghana. Histological evaluation and immunohistochemical staining for p16 and p53 were performed. Data were analysed using SPSS with associations between biomarker expression and clinicopathological variables (age, histological type, tumour grade) assessed.ResultsThe age range of the participants was 31–115 year with a mean age of 58.93 ± 17.88 years. Most cases (96.3%) were squamous cell carcinoma, with 49.6% being poorly differentiated. p16 was positively expressed in 71.11% of cases, while p53 showed 63.70% positivity. Significant associations were observed between p16 and tumour grade (p = 0.02), and between p53 and histological type (p = 0.021). No significant correlations were found between marker expression and age (p = 0.174).ConclusionThe high expression of p16 and p53, particularly in squamous and high-grade lesions, shows their potential role in early detection and prognostication of cervical cancer. These biomarkers may serve as cost-effective tools in resource-limited settings like Ghana, supporting improved clinical decision-making.Keyword: Cervical cancer, tissue microarray, immunohistochemistry, p16, p53 Introduction Non-communicable diseases (NCDs) contribute to the vast majority of mortality worldwide with cancer being the second leading cause of deaths [1–3] and the single most significant hindrance to raising life expectancy globally. Current data indicate that, approximately 41 million deaths of the 55 million global estimates were due to NCDs in 2019 [3]. That same year, 47% of NCDs deaths in low-and-middle-income countries (LMICs) occurred before the age of 70. In the following year, nearly 10 million deaths, equivalent to one in every six, were due to cancer, a little over 4 million deaths compared to 2018 estimates [4]. In 2020, the leading causes of cancer-related deaths were lung cancer, colorectal cancer, liver cancer, stomach cancer, and breast cancer, with approximately 400,000 children developing cancer each year [5]. The most prevalent types of cancer vary across countries, with cervical cancer being the most common in 23 nations [5] across continents including Latin America, Africa and the Caribbean and most part of the Asia. It is the fourth most common cancer among women globally with about 660,000 new cases, over 53% death toll in 2022 and about 94% of the deaths occurring in LMICs [6]. Cervical cancer incidence and mortality rates are highest in sub-Saharan Africa, Central America, and Southeast Asia [6]. Its rising incidence is attributed to multiple factors, including increased prevalence of risk factors associated with economic transitions. These include physical inactivity, obesity, smoking, changing reproductive behaviors, and population aging [7–10]. Additionally, variations in reproductive patterns such as early menarche, delayed childbearing, and infertility along with shifts toward high trans-fat diets and reduced physical activity, further contribute to the disease burden [11], while HIV patients are six times more likely to develop cervical cancer than the general population, with HIV linked to an estimated 5% of cases [12]. It is primarily caused by persistent infection with high-risk Human Papillomavirus (HPV) types 16 and 18, which are responsible for approximately 95% of all cases [6]. The disease disproportionately affects younger women, and as a result, 20% of children who lose their mother to cancer do so due to cervical cancer [13]. In West Africa, approximately 28,903 new cases are recorded annually, with mortality rates as high as 85–90% [14]. Recent studies further highlight the alarming trends in cervical cancer incidence and mortality in sub-Saharan Africa. A study by Jedy-Agba et al. [15] analyzed data from 10 population-based cancer registries in eight countries, revealing increasing incidence rates in nearly all regions except Mauritius, where a 2.5% annual decline was recorded. The highest increases were observed in Blantyre, Malawi (7.9% annual increase), Eldoret, Kenya (9.5% increase from 2002 to 2016), and Eastern Cape, South Africa. Meanwhile, a meta-analysis by Drokow et al. [16] found that five-year overall survival rates for cervical cancer varied significantly across Africa, with Ghana reporting a survival rate of 76.1%, while Malawi had a rate as low as 3.9%. In Ghana, cervical cancer is the leading cause of cancer-related deaths among women, with an estimated 3,151 new diagnoses and 2,119 deaths each year [17]. Despite the availability of screening tools such as the Pap smear, uptake remains low. While over 60% of women in developed countries undergo cervical cancer screening, fewer than 20% of women in Ghana, have ever been screened [18–21]. p16 and p53 are critical biomarkers in cervical cancer pathogenesis. p16, a cyclin-dependent kinase inhibitor, plays a crucial role in regulating the cell cycle by inhibiting retinoblastoma (Rb) protein phosphorylation, a tumor suppressor function that is disrupted in HPV-associated cervical cancer [22]. Several studies have shown a strong correlation between p16 overexpression and high-grade cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC) [22–24]. On the other hand, p53, often referred to as the “guardian of the genome,” functions as a tumor suppressor by inducing cell cycle arrest and apoptosis in response to cellular stress [25]. However, in cervical cancer, the HPV E6 oncoprotein targets p53 for ubiquitin-mediated degradation, effectively nullifying its tumor-suppressing capabilities and promoting uncontrolled cell proliferation [26]. Studies indicate that p53 expression is often absent or downregulated in cervical cancer cases, with some reports showing a higher prevalence of p53 in adenocarcinomas compared to squamous cell carcinoma [27, 28]. Recognizing the challenges associated with cervical cancer prevention and control, the World Health Organization (WHO) launched the Global Strategy to Accelerate the Elimination of Cervical Cancer in 2017 [29]. This strategy emphasizes the “90-70-90” targets: 90% of girls fully vaccinated with the HPV vaccine by age 15, 70% of women screened with a high-performance test by age 35 and again at 45, and 90% of women with cervical disease receiving treatment. This objective aligns with the focus of this study, which seeks to evaluate the expression of p16 and p53 biomarkers in cervical cancer tissue blocks and their relationship with age, histologic type and tumour grade in Kumasi, Ghana. Methods/materials Ethical clearance Ethical approval (Ref: CHRPE/AP/314/20) was obtained from the committee on Human Research, Publication and Ethics (CHRPE), Kwame Nkrumah University of Science and Technology (KNUST) and the Research and Development Unit, Komfo Anokye Teaching Hospital (KATH) (Reg No: RD/CR18/203) on “Molecular profiling of cervical cancer in Kumasi.’ Consent to participate was deemed unnecessary according to Committee on Human Research, Publication and Ethics guidelines of our institution. Study area and design This retrospective descriptive study was conducted between January 2015 and December 2016 at the KATH in Kumasi, Ghana. It aimed to evaluate the expression of p16 and p53 biomarkers in formalin-fixed paraffin-embedded (FFPE) cervical cancer tissues in relation with clinicopathological features. Samples collection and processing Patient demographics and histopathological details, including age, histologic type and tumor grade, were retrieved from pathology records. Archived FFPE tissue blocks of malignant cases were retrieved, and fresh histological sections were prepared. Standard tissue processing involved fixation in 10% buffered formalin, dehydration in graded alcohol, clearing with xylene, and embedding in paraffin [30]. Inclusion and exclusion criteria All consecutive malignant cases with available patient records and viable, preserved tissues were included. Cases with missing tissue blocks, incomplete records, inconclusive diagnoses, or mismatched tissue slides were excluded. Sample size A total of 135 consecutive cases meeting inclusion criteria were analysed using tissue microarray (TMA) and immunohistochemistry (IHC). Laboratory procedure This study involved three separate laboratory procedures. First was preparation of H&E-stained microscopic slides for histological tumour assessment, grading and mapping of tumour areas for construction of TMA, second was the construction of Tissue microarray (TMA) blocks, and finally Immunohistochemistry was performed for the TMA sections. Histologic slide preparation - microtomy Thin sections of the cervical tissues measuring about 3 μm were obtained using a semi-automated Rotary microtome, mounted on super frosted glass slides, dried, and deparaffinized with xylene. The tissues were then rehydrated through graded alcohol solutions (absolute alcohol (100%), 96% alcohol, 90% alcohol, 70% alcohol, 50% alcohol) and washed with Tris-buffered saline (TBS) for 5 min [30]. Haematoxylin and Eosin (H&E) staining Regressive H&E staining was employed [31]. Briefly, rehydrated sections were stained with hematoxylin for 8 min, washed under running tap water for 5 min, and differentiated using 1% acid alcohol. Bluing was performed in 0.2% ammonia water for 30 s, washed under running tap water and rinsed in 95% alcohol solution, followed by counterstaining with eosin. Slides were dehydrated using 95% alcohol and subsequently, absolute alcohol, cleared in series of xylene solutions, and mounted with DPX. H&E slide review The H&E slides were reviewed by two blinded pathologists, using Leica DM200 LED microscopes (Leica MICROSYSTEMS) according to the ESMO Clinical Practice Guidelines [32]. Tumour histological characteristics were updated, and representative areas of tumours were marked for TMA construction. Slides with marked-out tumour areas were matched with their corresponding tissue blocks and kept separately for TMA construction. TMA construction From TMA map, 1 mm tumour cores from 135 donor tissue blocks were introduced into TMA recipient paraffin blocks. The blocks were made using Leica EG1150 H Paraffin embedding station while Automated TMA machine (3DHISTECH, 2016) was used to introduce tissue cores. Two cores per case, and normal tissues from other body sites were inserted for quality assurance purposes. TMA slide preparation Same procedures employed for sectioning, slide preparation, deparaffinization and rehydration for H&E staining was followed in making the TMA slides. Sections were incubated overnight at 37 °C and subjected to Immunohistochemistry. Immunohistochemistry (IHC) Biomarker information AntibodyClonePre-treatDilutionControlCompanyAddressp53DO-7-1:40S95-13083DAKOCarpinteria CAp16DO-3-!:40TonsilDAKOCarpinteria CA Antigen retrieval TMA sections were microwaved in an antigen retrieval Citrate buffer (pH 6) for 15–20 min, cooled at room temperature and washed with distilled water. Blocking Endogenous peroxidase was inactivated with hydrogen peroxide-methanol solution for 15 min, washed in distilled water and rinsed in TBS. Casein buffer was used to prevent non-specific antibody binding. Primary and secondary antibodies Antibodies were diluted according to the manufacturers’ specification. Sections were incubated overnight in the various diluted antibodies for p16 and p53. A peroxidase-conjugated secondary antibody was applied for 30 min, followed by staining with 3,3-diaminobenzidine tetrahydrochloride (DAB) solution for 10 min. Counterstain using haematoxylin Sections were counterstained with haematoxylin, washed under running distilled water for 5 min, differentiated in 1% acid alcohol for 5–10 s, washed under running water for up to 15 min, until sections turned blue. Positive controls (tonsils) were included for all markers using tissues with known positive staining, while negative controls substituted primary antibodies with TBS. Data analysis Data were entered, cleaned and harmonized using Microsoft Excel 2016 and analysed using IBM SPSS Statistics version 26. Descriptive statistics were employed to summarize demographic and clinical characteristics. Continuous variables such as age were presented as means ± standard deviation, while categorical variables including histological type, tumour grade, and biomarker expression (p16 and p53) were expressed as frequencies and percentages. Comparative analyses were conducted to explore relationships between age and histopathological subtypes using One-Way Analysis of Variance. The associations between p16 and p53 expression and clinicopathological parameters were assessed using the Fisher’s Exact Test, given the small sample sizes within some subgroups. All statistical tests were two-tailed, and results were considered statistically significant at a p-value less than 0.05. IHC scoring For biomarker quantification, five randomly selected high-power fields were examined in uniformly stained slides. The presence of positive staining in TMA sections was evaluated, and tumour samples were categorized using a modified scoring system [33]: 0 for < 10% positive cells, 1 for 10%–40%, 2 for 40%–70%, and 3 for ≥ 70% positivity [34]. For p16, combined nuclear and cytoplasmic staining with intensity of over 10% was considered positive. For p53 staining, uniformly strong, diffuse nuclear expression in at least 10% of tumour cells was considered positive. Results A total of 135 cervical histologic samples were reviewed and analysed according to protocol to determine the expression status of p16 and p53 in cervical tissues and assess their relationship with age, histologic type and tumour grade. The ages of women diagnosed with cervical cancer ranged from 31 to 115 years with a mean of age of 58.93 (SD ± 17.88) and median age of 56 years consistent with the age group 50–59 years. A majority of the patients (54.1%) were below the mean age of 58 years (Table 1). Histologically, 91.9% (n = 124) of the cervical cases were classified as squamous cell carcinoma (SCC), while 3.7% (n = 5) were adenocarcinoma (ADC). Regarding tumour grade, Grade III (poorly differentiated) tumours constituted the highest proportion, accounting for 49.6% of all samples (Table 1). Table 1Clinicopathological characteristics of cervical cancer casesFrequencyn (135)PercentageAge group30–3940–4950–5960–6970–79> 802315382219181711.128.216.314.113.3Total135100Histological TypeSquamous Cell Carcinoma12491.9Basaloid Squamous Carcinoma64.4Adenocarcinoma53.7Tumour GradingGrade I (Well Differentiated)2317.0Grade II (Moderately Differentiated)4533.3Grade III (Poorly Differentiated)6749.6 Clinicopathological characteristics of cervical cancer cases 30–39 40–49 50–59 60–69 70–79 > 80 23 15 38 22 19 18 17 11.1 28.2 16.3 14.1 13.3 The mean age of patients varied across histologic types and tumour grades with SCC accounting for 60.09 years (SD ± 17.91) (Table 2). For tumour cells classified as Grade I (well-differentiated), the mean patient age was slightly higher at 62.96 years (SD ± 16.00). There was a statistically significant association between mean age and histological type of patients (p = 0.039). Table 2Comparison of mean age across histologic types and tumour gradesCharacteristicMean age ± SDP-valueHistological Type Squamous Cell Carcinoma60.09 (± 17.91) 0.039 Basaloid Squamous Cell Carcinoma46.00 (± 15.34) Adenocarcinoma45.6 (± 6.02)Tumour Grading Grade I (Well Differentiated cells)62.96 (± 16.00)0.123 Grade II (Moderately Differentiated cells)61.53 (± 14.72) Grade III (Poorly Differentiated cells)55.79 (± 19.97) Statistical significance was computed using one way ANOVA Comparison of mean age across histologic types and tumour grades Statistical significance was computed using one way ANOVA p16 was positively expressed in the majority of the cases 71.11% (96/135), with statistically significant correlation observed between p16 and tumour grade (p = 0.02), and a higher expression in well-and moderately differentiated cells. p53 expression 63.70% (86/135) showed no significant association with age (p = 0.17) or tumour grade (p = 0.44), but with histologic type (p = 0.021) (Table 3 and Fig. 1). Table 3Association between clinicopathological characteristics and biomarker expressionCharacteristicp16p53PositiveNegativeP-valuePositiveNegativeP-valueAge, mean ± SD58.48 (SD ± 18.62)60.44 (SD ± 16.69)0.58057.58 (SD ± 17.85)61.70 (SD ± 18.07)0.214Histological Type Squamous Cell Carcinoma86 (63.70%)35 (25.93%)0.27979 (58.52%)42 (31.11%) 0.021 Basaloid Squamous Cell Carcinoma6 (4.44%)-6 (2.96%)- Adenocarcinoma4 (2.96%)1 (0.74%)1 (0.74%)4 (2.96%)Tumour Grade Grade I18 (13.33%)2 (1.48%) 0.02 14 (10.37%)6 (4.44%)0.439 Grade II36 (26.67%)9 (6.67%)26 (19.26%)19 (14.07%) Grade III42 (31.11%)36 (26.67%)46 (34.07%)46 (34.07%) Statistical significance was computed using Fischer’s exact test Association between clinicopathological characteristics and biomarker expression Statistical significance was computed using Fischer’s exact test Photomicrographs of positive and control cases. A1 and B1 shows positive stain for p16 and p53 respectively, while A2 and B2 represent controls for the respective markers (x 40) Discussion Despite being one of the preventable cancers, cervical cancer continues to claim the lives of hundreds of women worldwide with the highest burden in developing countries especially Africa. The difference in mortality rates across the WHO regions is mainly due to the robust screening methods such as the pap smear and HPV DNA test. Notwithstanding the success of these methods, they still have limitations in their use. Early detection of the disease is very critical in its management which rests on the screening arm of the WHO strategy of 90-70-90. The study reported a mean age of 58.93 years which is consistent with studies conducted in Ghana [10, 35, 36]. The finding of this study contradicts that of Sarwath et al. [24] who published a lower mean age of 54.2 years. Several factors may explain this variation. Firstly, the majority of patients in the present study were within the post-menopausal age unlike Sarwath whose patients were within the reproductive age. Additionally, regional differences in healthcare access, use and health seeking behaviour as is the case in Ghana [21, 37] may contribute to delayed diagnosis with women potentially presenting at late stages due to limited routine screening or awareness. This study found the majority of the cases to be squamous cell carcinoma with mean age of 60.09 years (p = 0.039). The mean age-specific trend for SCC is slightly higher compared with global estimates of 55 years [38]. The proportion of SCC cases however, are in concordance with Titiloye et al. [36] (93.8%) and Der et al. [35] (90.1%) both studies in different regions of Ghana. These findings were however expected, as according to International Agency for Research on Cancer (IARC) (2020) [14], squamous cell carcinoma made up about 95% of cervical cancer cases in developing countries especially among older women. Given the anatomical and biological characteristics of cervical cancer, most cases occur at the squamous-columnar junction, an area where there is a transition from the endocervix to the ectocervix, which is predominantly made up of squamous cells. Again, studies in developed and developing countries have indicated SCC to be the most common histologic type due to high prevalence of HPV infections [38–44], which could be a reason for this finding, even though this current study did not assess HPV status. Only 3.3% of the cases were adenocarcinoma at 45.6 years mean age which is lower than the findings reported by Der et al. and Titiloye et al. who recorded 5.8% and 5.4% respectively [35, 36]. This trend of low ADC incidence and mean age-specific trend is consistent with patterns observed even in developed countries [38]. However, it is important to note that the ADC proportions in developed countries has declined over the years due to the implementation of effective ADC and SCC screening methods. High screening practices have led to earlier detection and prevention, thereby reducing the ADC incidence through the identification and management of precancerous lesions [38, 45]. Conversely, in low-resource settings, limited access to screening and delayed diagnosis [46–48] may contribute to the underrepresentation of adenocarcinoma cases in this study. The lack of structured screening programs, particularly for adenocarcinoma, means that this subtype may go undiagnosed or be detected at later stages, contributing to its lower recorded incidence. Furthermore, cultural barriers and healthcare accessibility issues in Ghana [21, 37] may exacerbate the situation, as women may not seek medical attention until symptoms are advanced, leading to skewed reporting in favour of more easily detectable squamous cell carcinoma. Majority of the tumours were high grade (Grade II and Grade III) with poorly differentiated squamous cells (Grade III) being the most common variant. This is similar to the findings of Titiloye et al. and Nartey et al. who also reported a higher percentage of high-grade lesions [36, 37]. This reiterates the fact that most patients in Sub-Saharan Africa present with high grade lesions which is in contrast with that of developed countries which reports a lower percentage of high-grade lesions [38]. This pattern could be attributed to early presentation and vaccination programs in contrast to a developing country with several challenges such as high incidence of poverty, inaccessibility to health care, negative religious and cultural beliefs, ignorance, and most importantly late presentation to the hospitals [21, 46, 48]. This study reported an insignificant but increased expression of p16 in cervical cancer tissues, with overall positivity rate of 71.11%. Among these, 63.70% of SCC cases and 3.0% of ADC cases were p16 positive (p = 0.279). Although not statistically significant, the findings suggest a predominant expression of p16 in SCC, consistent with the established role of p16 as a surrogate biomarker for high-risk HPV (hrHPV) infections, particularly HPV types 16 and 18, which are highly implicated in the pathogenesis of SCC [49–51]. The high expression of p16 in our study is consistent with studies in Thailand [52], Iran [23, 53] and China [54]. The expressions on SCC were above 90%, while its expression on ADC was above 75% [53, 54], figures that are higher compared to our study. These differences may be attributed to geography, technical variability in IHC staining and scoring protocols and sample size. Interestingly, our study’s results corroborate the insignificant correlation with age and histologic type in the study of Kanthiya et al. [52]. This suggests that p16 overexpression in cervical cancer is more closely related to the presence of high-risk HPV than to the patient’s age [51], emphasising its use as a molecular marker for HPV-driven transformation, rather than a demographic indicator. One limitation in our study was that we did not assess HPV which would have added more value and corroborated the assertion of surrogacy. Furthermore, the expression of p16 was found to significantly increase with higher histological grades of cervical cancer (p = 0.02), with the majority (31.11%) of positive cases observed in poorly differentiated (high-grade) lesions. This trend suggests that p16 overexpression is more pronounced in advanced tumour grades, supporting its role in the progression of cervical neoplasia. Similar observations have been reported by Sarwath et al. [24] and Izadi-Mood et al. [53], both of whom identified a positive correlation between p16 expression and tumour grade, stressing its potential as a marker of tumour aggressiveness and cellular dysregulation. However, these findings are in contrast to Lin et al. [55], who reported no significant association between histological grade and p16 expression. This discrepancy could be attributed to differences in sample size, scoring criteria, or the distribution of tumour subtypes across studies. It may also reflect regional differences in HPV genotype prevalence, as different viral oncogenes may exert varying influences on p16 expression and cell cycle regulation [56]. Biologically, the overexpression of p16 in cervical cancer is largely attributed to the inactivation of the retinoblastoma protein (pRb) by high-risk HPV E7 oncoproteins, leading to uncontrolled cell cycle progression. Under normal circumstances, p16 functions as a tumour suppressor, inhibiting cyclin-dependent kinases to regulate the G1/S checkpoint of the cell cycle. However, in the presence of persistent hrHPV infection, the negative feedback loop between pRb and p16 is disrupted, resulting in compensatory overexpression of p16. This phenomenon has become a hallmark of HPV-related cervical neoplasms [49, 57]. Therefore, the observed pattern in this study where p16 expression increases with tumour grade, is biologically plausible and reinforces the use of p16 as a surrogate marker for hrHPV oncogenic activity, particularly in high-grade lesions where viral-induced cellular transformation is most pronounced. In this study, 63.70% (86/135) of the cervical cancer cases showed positive expression of p53, with the majority of these 58.52% occurring in SCC and only 0.8% in ADC, a pattern reflecting a significant association between p53 expression and histologic type (p = 0.021). Our overall high positivity rate aligns with that of a study conducted in China [54], which reported p53 expression in 56.8% of cervical cancer cases and 75.3% in a study conducted in Algeria [28] (but lower SCC positivity, 24.68%), supporting the notion that p53 accumulation is a common event in cervical carcinogenesis, particularly in SCC. On the contrary, our result was not consistent with the results reported by Chaloob et al. [58] and Garima et al. [27] who showed a high positivity rate in ADC (58.3% and 50.0% respectively) than in SCC. These inconsistencies may be attributed to differences in population demographics, HPV genotype distribution, sample size, or immunohistochemical protocols. The role of p53 in cervical cancer remains multi-layered and, at times, controversial. As a tumour suppressor protein, p53 regulates key cellular processes like apoptosis, DNA repair, and cell cycle arrest [27, 54, 59]. In HPV-associated cervical cancers, the E6 oncoprotein of high-risk HPV types binds and degrades wild-type p53, contributing to unchecked cell proliferation [26, 50, 53]. This degradation limits its detection by immunohistochemistry due to its short physiological half-life, as noted by Deffar et al. [28]. However, when p53 is mutated, its conformation changes, extending its half-life and making it detectable by IHC [60]. This accumulation is often seen in more advanced or aggressive lesions. Additionally, p53 overexpression may occur in tumours driven by non-HPV oncogenic pathways or by other high-risk HPV strains with varied mechanisms of p53 interaction [26, 50]. Conclusion The findings of this study suggest that immunohistochemical expression of p16 and p53 may serve as important adjunct biomarkers for early detection, risk stratification, and prognostication of cervical cancer. The expression profile of p16 may serve as surrogate marker of HPV expression in cervical cancer. Their expression profiles can provide understandings into tumour behaviour, potentially guide treatment decisions. Acknowledgements Miss Ashley Pelton of Dana Faber Cancer Center, Brigham and Women Hospital for her support in construction of TMA and performing IHC. Authors’ contributions BMD Conceptualised the study, reviewed all slides, performed IHC, prepared all figures and revised the main manuscript; BNOM, EKA, LS and KBA collected data and wrote the main manuscript text. All authors reviewed the manuscript.” Funding The study received no funding. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent participate Ethical approval (Ref: CHRPE/AP/314/20) was obtained from the Committee on Human Research, Publication and Ethics (CHRPE), Kwame Nkrumah University of Science and Technology (KNUST) and the Research and Development Unit, Komfo Anokye Teaching Hospital (KATH) (Reg No: RD/CR18/203) on “Molecular profiling of cervical cancer in Kumasi.’ All experiments were performed according to the guidelines as provide by the Declaration of Helsinki. Consent to participate was deemed unnecessary according to Committee on Human Research, Publication and Ethics guidelines of our institution. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.